MedTrace Logo

Residual Platelet Activity In Advanced Peripheral Artery Disease

NCT01627431 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 410

Last updated 2012-11-28

No results posted yet for this study

Summary

The peripheral arterial disease (PAD) is a common atherosclerotic disease manifestation and its prevalence increase with age and with the simultaneous presence of cardiovascular risk factors.

PAD patients are usually treated, as a first line treatment, with the exercise therapy, combined with the pharmacological antiplatelet therapy.

In the case of first line therapy failure, PAD patients usually undergoing to invasive revascularization procedures.

After a peripheral stent has been located, the major follow-up problem is the restenosis rate.

Published studies describe how, in a large amount of patients, can be recognised an high residual platelet activity. These data about PAD patients at the moment are lacking .

The authors would evaluate the incidence of PAD patients with an high residual platelet activity.

Conditions

  • Peripheral Arterial Disease

Interventions

DRUG

Acetylsalicylic acid

100 mg once per day

DRUG

Clopidogrel

75 mg once per day

Sponsors & Collaborators

  • University of Florence

    collaborator OTHER

  • University of Roma La Sapienza

    lead OTHER

Principal Investigators

  • Francesco Violi, MD · Divisione di Prima Clinica Medica - Sapienza University of Rome

  • Rosanna Abate, MD · Azienda Ospedaliero-Universitaria Careggi University of Florence

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2014-07-31
Completion
2015-07-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01627431 on ClinicalTrials.gov